Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC)
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …

The therapeutic effect of highly malignant triple negative breast cancer (TNBC) is negatively
affected by the formation of tumor cell resistant clone and the severe toxicity of …

Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a
subgroup harboring evidence of defective homologous recombination (HR) DNA repair …

Triple-negative breast cancer is a heterogeneous disease and specific therapies have not
been available for a long time. Therefore, conventional chemotherapy is still considered the …

Abstract Purpose: BRCA1/2-mutated and some sporadic triple-negative breast cancers
(TNBC) have DNA repair defects and are sensitive to DNA-damaging therapeutics …

ABSTRACT The 14th St Gallen International Breast Cancer Conference (2015) reviewed
substantial new evidence on locoregional and systemic therapies for early breast cancer …

Triple-negative breast cancer (TNBC) is defined as a type of breast cancer with lack of
expression of estrogen receptor (ER), progesterone receptor (PR) and HER2 protein. The …

Drug resistance is a major challenge in cancer treatment. Emerging evidence indicates that
deregulation of YAP/TAZ signaling may be a major mechanism of intrinsic and acquired …

Triple negative breast cancer (TNBC) is a complex and aggressive subtype of breast cancer
which lacks oestrogen receptors, progesterone receptors and HER2 amplification, thereby …

Abstract Background In the neoadjuvant GeparSixto study, adding carboplatin to taxane-and
anthracycline-based chemotherapy improved pathological complete response (pCR) rates …